{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:37:39Z","timestamp":1790753859620,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Friedrich Baur foundation"},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["KA2274\/3-1"],"award-info":[{"award-number":["KA2274\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"name":"G\u00e4nsebl\u00fcmchen-Voerde foundation"}],"content-domain":{"domain":["ejcancer.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.ejca.2011.12.032","type":"journal-article","created":{"date-parts":[[2012,1,30]],"date-time":"2012-01-30T16:42:22Z","timestamp":1327941742000},"page":"2442-2450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment options in high-risk patients"],"prefix":"10.1016","volume":"48","author":[{"given":"Ferdinand","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Henningsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Eichenm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"G\u00f6deke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"M\u00fcller-H\u00f6cker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich von","family":"Schweinitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Kappler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2011.12.032_b0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/j.sempedsurg.2005.11.004","article-title":"Management of liver tumors in childhood","volume":"15","author":"von Schweinitz","year":"2006","journal-title":"Semin Pediatr Surg"},{"issue":"3","key":"10.1016\/j.ejca.2011.12.032_b0010","first-page":"159","article-title":"Differentiated treatment protocols for high- and standard-risk hepatoblastoma \u2013 an interim report of the German Liver Tumor Study HB99","volume":"215","author":"Haberle","year":"2003","journal-title":"Klin Padiatr"},{"issue":"17","key":"10.1016\/j.ejca.2011.12.032_b0015","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1056\/NEJMoa0810613","article-title":"Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma","volume":"361","author":"Perilongo","year":"2009","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ejca.2011.12.032_b0020","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1200\/JCO.2009.22.4857","article-title":"Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study","volume":"28","author":"Zsiros","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2011.12.032_b0025","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/cncr.10858","article-title":"The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: clinical course and in vivo model","volume":"95","author":"Warmann","year":"2002","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2011.12.032_b0030","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/hep.22649","article-title":"Blocking the hedgehog pathway inhibits hepatoblastoma growth","volume":"49","author":"Eichenmuller","year":"2009","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ejca.2011.12.032_b0035","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/sj.onc.1203356","article-title":"Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas","volume":"19","author":"Wei","year":"2000","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.ejca.2011.12.032_b0040","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1054\/bjoc.1999.1179","article-title":"Altered expression of members of the IGF-axis in hepatoblastomas","volume":"82","author":"Gray","year":"2000","journal-title":"Br J Cancer"},{"issue":"14","key":"10.1016\/j.ejca.2011.12.032_b0045","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1158\/1078-0432.CCR-08-2878","article-title":"Activation of phosphatidylinositol-3\u2032-kinase\/AKT signaling is essential in hepatoblastoma survival","volume":"15","author":"Hartmann","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3\u20134","key":"10.1016\/j.ejca.2011.12.032_b0050","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s10555-007-9077-8","article-title":"Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis","volume":"26","author":"Seeliger","year":"2007","journal-title":"Cancer Metastasis Rev"},{"issue":"5","key":"10.1016\/j.ejca.2011.12.032_b0055","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1593\/neo.05820","article-title":"CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR\/Hif-1alpha\/VEGF signaling","volume":"8","author":"Wan","year":"2006","journal-title":"Neoplasia"},{"issue":"2","key":"10.1016\/j.ejca.2011.12.032_b0060","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ijc.10914","article-title":"Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN","volume":"104","author":"Misawa","year":"2003","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2011.12.032_b0065","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ejca.2011.12.032_b0070","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2011.12.032_b0075","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1471-2407-10-190","article-title":"A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma","volume":"10","author":"Schnitzbauer","year":"2010","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2011.12.032_b0080","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s10147-007-0733-3","article-title":"Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer","volume":"13","author":"Rizell","year":"2008","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2011.12.032_b0085","first-page":"1","article-title":"Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma","volume":"67","author":"Doi","year":"1976","journal-title":"Gann"},{"issue":"4","key":"10.1016\/j.ejca.2011.12.032_b0090","first-page":"809","article-title":"Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma","volume":"74","author":"Pietsch","year":"1996","journal-title":"Lab Invest"},{"issue":"10","key":"10.1016\/j.ejca.2011.12.032_b0095","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.humpath.2009.07.003","article-title":"Hep G2 is a hepatoblastoma-derived cell line","volume":"40","author":"Lopez-Terrada","year":"2009","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.ejca.2011.12.032_b0100","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.bjc.6605715","article-title":"Betulinic acid induces apoptosis and inhibits hedgehog signalling in rhabdomyosarcoma","volume":"103","author":"Eichenmuller","year":"2010","journal-title":"Br J Cancer"},{"issue":"9637","key":"10.1016\/j.ejca.2011.12.032_b0105","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ejca.2011.12.032_b0110","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1200\/JCO.2005.23.622","article-title":"Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study","volume":"23","author":"Galanis","year":"2005","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2011.12.032_b0115","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1200\/JCO.2005.66.130","article-title":"Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer","volume":"23","author":"Chan","year":"2005","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2011.12.032_b0120","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2011.12.032_b0125","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/pbc.23124","article-title":"Sirolimus for the treatment of complicated vascular anomalies in children","volume":"57","author":"Hammill","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2011.12.032_b0130","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1399-3046.2003.00137.x","article-title":"Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis","volume":"8","author":"Tejani","year":"2004","journal-title":"Pediatr Transplant"},{"issue":"1","key":"10.1016\/j.ejca.2011.12.032_b0135","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2008.03.024","article-title":"Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma","volume":"49","author":"Piguet","year":"2008","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.ejca.2011.12.032_b0140","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1399-3046.2011.01515.x","article-title":"The use of everolimus in pediatric liver transplant recipients: first experience in a single center","volume":"15","author":"Nielsen","year":"2011","journal-title":"Pediatr Transplant"},{"issue":"20","key":"10.1016\/j.ejca.2011.12.032_b0145","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1158\/1078-0432.CCR-04-0112","article-title":"Activation of the Akt\/mammalian target of rapamycin\/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers","volume":"10","author":"Zhou","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2011.12.032_b0150","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jhep.2008.08.010","article-title":"ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft","volume":"49","author":"Jasinghe","year":"2008","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.ejca.2011.12.032_b0155","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/0008-5472.CAN-3554-2","article-title":"Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells","volume":"64","author":"Boulay","year":"2004","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2011.12.032_b0160","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/ijc.22442","article-title":"Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model","volume":"120","author":"Lang","year":"2007","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2011.12.032_b0165","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1111\/j.1523-1755.2005.00731.x","article-title":"Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy","volume":"68","author":"Hartmann","year":"2005","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.ejca.2011.12.032_b0170","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/pbc.22740","article-title":"Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells","volume":"55","author":"Lieber","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2011.12.032_b0175","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/pbc.23069","article-title":"Prognostic implications of serum alpha-fetoprotein response during treatment of hepatoblastoma","volume":"57","author":"Koh","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"13","key":"10.1016\/j.ejca.2011.12.032_b0180","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism","volume":"26","author":"Wan","year":"2007","journal-title":"Oncogene"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491200007X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491200007X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T14:28:33Z","timestamp":1543242513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491200007X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":36,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S095980491200007X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2011.12.032","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment options in high-risk patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2011.12.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}